标准化尘螨变应原制剂治疗变应性鼻炎的不良反应观察

发布时间：2018-09-14 19:00

【摘要】：目的:通过观察标准化尘螨变应原制剂治疗变应性鼻炎(AR)的不良反应,评价特异性免疫治疗的安全性。方法:使用安脱达标准化尘螨变应原制剂皮下注射治疗386例AR患者,观察其不良反应发生情况并计算不良反应发生率。结果:386例AR患者较明显的不良反应发生率为10.9%(42/386),其中大的局部不良反应发生率为2.6%(10/386),全身不良反应发生率为9.3%(36/386),其中轻度全身反应(1级)34例,中度全身反应(2级)1例,严重(非致命)全身反应(3级)1例,无一例患者发生过敏性休克(4级);3种治疗方案不良反应的发生率以常规方案最高(21.1%),成人集群方案居次(11.9%),儿童集群方案最低(1.5%);不良反应大多发生在剂量递增阶段中后期及维持治疗阶段早期。结论:对AR患者进行规范的特异性免疫治疗是一种安全有效的对因治疗方法,严格掌握治疗流程并执行操作规范,同时采取针对性措施可减少不良反应的发生。
[Abstract]:Objective: to evaluate the safety of specific immunotherapy by observing the adverse reactions of standardized dust mite allergen in the treatment of allergic rhinitis (AR). Methods: 386 patients with AR were treated by subcutaneous injection of Amida standardized dust mite allergen. The adverse reactions were observed and the incidence rate of adverse reactions was calculated. Results the incidence of adverse reactions was 10.9% (42 / 386) in patients with AR. The incidence of major local adverse reactions was 2.6% (10 / 386), and the incidence of systemic adverse reactions was 9.3% (36 / 386). There were 34 cases of mild systemic reactions (grade 1) and 1 case of moderate systemic reactions (grade 2). Severe (non-fatal) systemic reaction (grade 3), No patient with anaphylactic shock (grade 4) had the highest incidence of adverse reactions (21.1%), adult cluster (11.9%) and children (1.5%) had the highest incidence of adverse reactions, and most of the adverse reactions occurred in the dose-increasing phase. Late stage and early stage of maintenance therapy. Conclusion: the standard specific immunotherapy for AR patients is a safe and effective method to treat the cause, strictly master the treatment process and carry out the operation standard, and take targeted measures to reduce the occurrence of adverse reactions.
【作者单位】：南昌大学第一附属医院耳鼻咽喉-头颈外科;
【分类号】：R765.21

【参考文献】